248 Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naïve or with previous inadequate response to tumour necrosis factor inhibitor therapy

Autor:	Andrew J Bradley, Katrien Van Beneden, Mani H Nassab, Deepak R. Jadon, Georg Pum
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Necrosis Tumor necrosis factors business.industry medicine.disease Disease activity Ixekizumab Psoriatic arthritis Rheumatology Internal medicine medicine Pharmacology (medical) In patient medicine.symptom business
Zdroj:	Rheumatology. 58
ISSN:	1462-0332 1462-0324
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::de2a7a7a4245403bf2a5ba508d83d958 https://doi.org/10.1093/rheumatology/kez107.064 Zobrazit plný text záznamu